Evidence map›Paper›PMID 30515523›Full record

ArticlePsychopharmacology2019

Minocycline prevents the development of depression-like behavior and hippocampal inflammation in a rat model of Alzheimer's disease.

Mohammad Amani, Ghaffar Shokouhi, Ali-Akbar Salari

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 60 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Depression, dementia and immune dysregulation.Brain : a journal of neurology · 2021
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 3 countries.

Mohammad AmaniDepartment of Physiology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
Ghaffar ShokouhiDrug Applied Research Center, Tabriz University of Medical Sciences, P.O. Box 51656-65811, Tabriz, Iran.
Ali-Akbar SalariDrug Applied Research Center, Tabriz University of Medical Sciences, P.O. Box 51656-65811, Tabriz, Iran. aa.salari@yahoo.com.ORCID http://orcid.org/0000-0002-4970-0337
Tabriz University of Medical Sciences · IRUniversity of California, Irvine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleConsiderable clinical and experimental studies have shown that depression-related disorders are the most common neuropsychiatric symptoms in Alzheimer's disease (AD), affecting as many as 20-40% of patients. An increasing amount of evidence shows that monoamine-based antidepressant treatments are not completely effective for depression treatment in patients with dementia. Minocycline, a second-generation tetracycline antibiotic, has been gaining research and clinical attention for the treatment of different neuropsychiatric disorders, and more recently depression symptom in humans.

methodsIn the present study, we investigated the effects of Aβ1-42 administration alone or in combination with minocycline treatment on depression-like behaviors and anti/pro-inflammatory cytokines such as interleukin(IL)-10, IL-β, and tumor necrosis factor (TNF)-α in the hippocampus of rats.

resultsOur results showed that Aβ1-42 administration increased depression-related behaviors in sucrose preference test, tail suspension test, novelty-suppressed feeding test, and forced swim test. We also found significant increases in IL-1β and TNF-α levels in the hippocampus of Aβ1-42-treated rats. Interestingly, minocycline treatment significantly reversed depression-related behaviors and the levels of hippocampal cytokines in Aβ1-42-treated rats.

conclusionThese findings support the idea that there is a significant relationship among AD, depression-related symptoms, and pro-inflammatory cytokines in the brain, and suggest that antidepressant-like impacts of minocycline could be due to its anti-inflammatory properties. This drug could be of potential interest for the treatment of depression in patients with Alzheimer's disease.

Indexed as

Disease Models, AnimalAlzheimer DiseaseAmyloid beta-PeptidesAnimalsAntidepressive AgentsCytokinesDepressionHindlimb SuspensionHippocampusInflammationInflammation MediatorsMaleMinocyclinePeptide FragmentsRatsRats, WistarAmyloid beta-Peptidesamyloid beta-protein (1-42)Antidepressive AgentsCytokinesInflammation MediatorsMinocyclinePeptide FragmentsTumor Necrosis Factor-alphaAffective disordersAntibioticsImmune systemNeurodegenerative diseaseβ-Amyloid

Identifiers

PMID30515523
OpenAlexW2902129006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.